Provectus (PVCT) president receives grant of Series D-1 convertible preferred stock
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
PROVECTUS BIOPHARMACEUTICALS, INC. reported that President and director Dominic Rodrigues received a grant of 45,860 shares of Series D-1 Convertible Preferred Stock at a price of $0.00 per share. Each preferred share is convertible into 10 shares of common stock, representing 458,600 underlying common shares. After this grant, Rodrigues holds 1,383,736 shares of Series D-1 Preferred Stock, which will automatically convert into common stock on December 31, 2028 unless converted earlier under the series’ terms.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Rodrigues Dominic
Role
PRESIDENT
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Series D-1 Convertible Preferred Stock | 45,860 | $0.00 | -- |
Holdings After Transaction:
Series D-1 Convertible Preferred Stock — 1,383,736 shares (Direct, null)
Footnotes (1)
- Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on December 31, 2028, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.
Key Figures
Series D-1 preferred granted: 45,860 shares
Grant price: $0.00 per share
Underlying common shares: 458,600 shares
+3 more
6 metrics
Series D-1 preferred granted
45,860 shares
Grant on June 30, 2026
Grant price
$0.00 per share
Series D-1 preferred grant
Underlying common shares
458,600 shares
10 common shares per preferred share
Series D-1 holdings after
1,383,736 shares
Preferred shares held after transaction
Conversion ratio
10 common per preferred share
Series D-1 Convertible Preferred Stock
Automatic conversion date
December 31, 2028
Series D-1 automatic conversion to common
Key Terms
Series D-1 Convertible Preferred Stock, convertible, automatic convert, Certificate of Designation
4 terms
Series D-1 Convertible Preferred Stock financial
"Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock"
convertible financial
"Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on December 31, 2028"
A convertible is a type of investment that starts as a loan or preferred stake (like a bond or preferred share) but can be exchanged for common shares of the company at a set price or under certain conditions. It matters to investors because it offers a mix of steady income and downside protection like a loan, plus the upside of stock ownership if the company does well—similar to holding a coupon that you can trade for a full ticket if the event becomes valuable.
automatic convert financial
"will automatically convert into Common Stock on December 31, 2028, unless earlier converted"
Certificate of Designation regulatory
"in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock"
A certificate of designation is a formal document that spells out the specific rights and rules attached to a particular class or series of stock, usually preferred shares. Think of it as a rulebook or menu that lists dividend terms, liquidation priority, conversion or redemption rights and any special voting protections; investors use it to judge how much income, control or downside protection those shares will provide compared with other securities.
FAQ
What insider transaction did PVCT report for Dominic Rodrigues on this Form 4?
Dominic Rodrigues received a grant of 45,860 shares of Series D-1 Convertible Preferred Stock at $0.00 per share. This is a compensation-type acquisition, not an open-market purchase or sale of Provectus Biopharmaceuticals common stock.
What are Dominic Rodrigues’ Series D-1 preferred holdings after this PVCT transaction?
After the grant, Dominic Rodrigues holds 1,383,736 shares of Series D-1 Convertible Preferred Stock. These holdings are reported as directly owned and provide potential future conversion into common stock based on the series’ 10-for-1 conversion ratio.
When will the PVCT Series D-1 Convertible Preferred Stock automatically convert?
The Series D-1 Convertible Preferred Stock will automatically convert into common stock on December 31, 2028, unless it is converted earlier in line with the Certificate of Designation terms governing this preferred series.
Did this PVCT Form 4 show any open-market buys or sells of common stock?
No. The Form 4 shows a grant of Series D-1 Convertible Preferred Stock, classified as a derivative acquisition. There were no reported open-market purchases or sales of Provectus Biopharmaceuticals common stock in this filing.